Frontiers in Immunology is a leading open-access journal published by FRONTIERS MEDIA SA since 2010, dedicated to advancing knowledge in the field of immunology. With an impressive Q1 ranking in both Immunology and Allergy as of 2023, this journal exemplifies excellence in research dissemination, positioning itself among the top 22% of relevant literature in the discipline. The journal, based in Switzerland, emphasizes its commitment to open science by ensuring all published research is freely accessible, fostering collaboration and innovation among researchers, professionals, and students alike. With substantial visibility demonstrated by its ranks within the Scopus database—ranked #52 out of 233 in Immunology and Allergy, and #58 out of 236 in Immunology and Microbiology—Frontiers in Immunology serves as a vital platform for cutting-edge research. Researchers are invited to contribute original investigations and reviews that expand the understanding of immune mechanisms, therapeutic advancements, and clinical applications, making it a cornerstone for those looking to push the boundaries of immunological science.

Scandinavian Journal of Immunology is a prestigious peer-reviewed journal published by Wiley, focused on the evolving field of immunology and its interdisciplinary ties with medicine. Since its inception in 1972, this journal has cultivated a rich repository of knowledge, showcasing innovative research and reviews that contribute to the understanding of immune system functions, disorders, and therapeutic interventions. With an impressive impact factor reflecting a Q2 ranking in Immunology and a top-tier Q1 status in miscellaneous Medicine categories for 2023, it is recognized for its high-quality scholarly output, positioning it among the leading journals in the field. Additionally, its Scopus ranking of #84 out of 236 in Immunology underscores its significance and relevance to both emerging and established researchers. Although it does not currently offer open access options, the journal’s expansive reach and rigorous publication standards make it an essential platform for disseminating impactful research to the global scientific community. The journal invites submissions that explore the complexities of the immune system, aiming to bridge clinical and basic science for a comprehensive understanding of immunological phenomena.

Clinical and Experimental Immunology, published by Oxford University Press, is a premier journal that has been a cornerstone in the field of immunology since its inception in 1966. With an ISSN of 0009-9104 and an E-ISSN of 1365-2249, this journal holds a significant position in academic research, currently ranking in the Q2 category for both Immunology and Allergy (2023). Its impactful contributions are reflected in its Scopus rankings, where it stands at Rank #63 out of 233 in Immunology and Allergy, placing it in the 73rd percentile, and Rank #73 out of 236 in Immunology and Microbiology. Researchers, healthcare professionals, and students will find this journal an invaluable resource for cutting-edge studies, reviews, and clinical advancements in the ever-evolving domain of immunology. While the publication does not offer open-access options, it remains a pivotal platform for disseminating knowledge that impacts both clinical practice and experimental research.

Cancer Immunology Immunotherapy, published by Springer, stands as a premier journal in the fields of cancer research and immunology, holding a prestigious Q1 ranking across multiple categories, including Oncology and Medicine as of 2023. With an ISSN of 0340-7004 and an E-ISSN of 1432-0851, this journal has been a pivotal platform for groundbreaking research since its inception in 1976, continuing to provide insight into the complex interactions between the immune system and cancer. The journal's scope encompasses a wide array of topics, including novel therapeutic strategies, immunological mechanisms, and translational science aimed at advancing treatment outcomes for cancer patients. Renowned for its rigorous peer-review process and high impact factor, it attracts contributions from leading experts and researchers around the globe, positioning itself among the top-tier publications with Scopus rankings that reflect its vital role in advancing the field. Access options are generally subscription-based, ensuring a comprehensive resource for professionals and academics seeking to deepen their understanding and make meaningful contributions to cancer immunotherapy.

Welcome to Immuno, a pioneering open-access journal published by MDPI that serves as a key platform for the dissemination of innovative research in the fields of immunology, biochemistry, and genetics. Established in 2021, this journal has rapidly established itself within the academic community, currently ranking in the 53rd percentile in Medicine (miscellaneous) and 50th percentile in Biochemistry, Genetics, and Molecular Biology according to Scopus metrics. With a commitment to advancing our understanding of immune mechanisms and their applications in health and disease, Immuno is dedicated to publishing high-quality peer-reviewed articles that contribute valuable insights to both researchers and practitioners. Positioned in the heart of Switzerland, its global accessibility and diverse editorial board are a testament to its aim to promote knowledge exchange among scientists, practitioners, and students alike. Explore the latest discoveries and advancements in immunological research through Immuno, where your contributions help shape the future of this critical area of study.

Science Immunology, published by the American Association for the Advancement of Science, is a leading journal in the field of immunology, recognized for its significant impact and rigor in advancing our understanding of immune responses and complex diseases. With an impressive impact factor that places it in the Q1 category of both immunology and allergy, as well as miscellaneous medicine, this journal is ranked #7 and #8 in their respective Scopus categories, reflecting its high-quality research output. Since its inception in 2016, Science Immunology has been at the forefront of interdisciplinary immunological research, fostering crucial insights that link immunology with pressing health challenges. The journal is committed to providing open access to its content, ensuring that groundbreaking findings are accessible to a global audience of researchers, professionals, and students. Its anthology not only addresses fundamental immunological mechanisms but also enhances the dialogue on translational applications and therapeutic interventions, solidifying its position as an essential resource within the scientific community.

MOLECULAR IMMUNOLOGY, published by Pergamon-Elsevier Science Ltd in the United Kingdom, is a highly regarded journal in the fields of Immunology and Molecular Biology. With a focus on advancing the understanding of the immune system at the molecular level, the journal has been a critical resource since its inception in 1975. The journal is currently listed in the second quartile (Q2) of its category as per the 2023 rankings, indicating its substantial impact in both Immunology and Molecular Biology research. Researchers and professionals benefit from the journal's rigorous peer-review process and its commitment to publishing high-quality original research, reviews, and methodological studies that explore the intricate dynamics of immune responses. Although it does not currently offer an open access option, MOLECULAR IMMUNOLOGY remains an essential platform for scholars, emphasizing the significance of molecular interactions within the immune system and their implications in health and disease.

Immunotherapy Advances, published by Oxford University Press, stands at the forefront of the rapidly evolving field of immunology and microbe interactions, focusing specifically on novel immunotherapeutic strategies and their clinical applications. Established in 2021, this peer-reviewed journal aims to disseminate high-quality research that contributes to the understanding and advancement of immunotherapeutic techniques, potentially transforming patient care in immunology. With a current Scopus rank of #140 out of 236 in the realm of Immunology, placing it in the 40th percentile, Immunotherapy Advances is positioned to be an integral resource for researchers, healthcare professionals, and students eager to stay updated with groundbreaking findings and methodologies. The journal is dedicated to fostering innovative discussions and collaborations, ensuring open access to vital research that influences treatment paradigms globally.

International Immunopharmacology, published by Elsevier, stands as a prominent journal within the disciplines of immunology and pharmacology. With an ISSN of 1567-5769 and an E-ISSN of 1878-1705, this esteemed journal is based in the Netherlands and features a robust commitment to disseminating high-quality research from its inception in 2001 through 2024. The journal has achieved impressive rankings, securing a Q1 category in Pharmacology and Q2 in both Immunology and Immunology and Allergy as of 2023. With its strategic focus on bridging the gap between immunology and pharmacological applications, International Immunopharmacology attracts a diverse readership, including researchers, healthcare professionals, and students interested in the latest advancements in therapeutic agents and immune system modulation. Furthermore, it offers an open access option, enhancing the accessibility and reach of its invaluable content. As a pivotal resource in the field, this journal not only facilitates the exchange of innovative ideas but also fosters a deeper understanding of the complexities of immunopharmacology in today’s research landscape.

IMMUNOLOGY is a premier journal published by Wiley that has been at the forefront of the field since its inception in 1958. With an impressive impact factor and classified in the Q1 quartile for both Immunology and Allergy as of 2023, this journal is highly regarded among researchers and professionals alike. It ranks 36th out of 233 in the Medicine/Immunology and Allergy category, and 40th out of 236 in the Immunology and Microbiology segment on Scopus, placing it firmly within the top percentile of its field. The journal is dedicated to publishing high-quality research that advances our understanding of immunological processes, bridging basic science with clinical applications. Although it does not operate under an open-access model, it offers conventional access options that remain integral to the dissemination of vital immunological research. With its broad scope and commitment to scholarly excellence, IMMUNOLOGY continues to serve as an essential resource for those seeking the latest advancements in immunology, fostering innovation and collaboration among scientists globally.